Completed OBSERVATIONAL NCT00897442

Collecting Tumor Samples From Patients With Gynecological Tumors

Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer

Sponsor: Gynecologic Oncology Group

Conditions Borderline Ovarian Clear Cell Tumor Borderline Ovarian Serous Tumor Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Small Cell Carcinoma Cervical Squamous Cell Carcinoma, Not Otherwise Specified Childhood Embryonal Rhabdomyosarcoma Childhood Malignant Ovarian Germ Cell Tumor Endometrioid Stromal Sarcoma Gestational Trophoblastic Tumor Malignant Mesothelioma Malignant Ovarian Epithelial Tumor Melanoma Neoplasm of Uncertain Malignant Potential Ovarian Brenner Tumor Ovarian Clear Cell Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Paget Disease of the Vulva Recurrent Cervical Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Germ Cell Tumor Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Recurrent Vaginal Carcinoma Recurrent Vulvar Carcinoma Stage I Ovarian Cancer Stage I Uterine Corpus Cancer Stage I Vaginal Cancer Stage I Vulvar Cancer Stage IA Cervical Cancer Stage IA Fallopian Tube Cancer Stage IA Ovarian Cancer Stage IA Ovarian Germ Cell Tumor Stage IB Cervical Cancer Stage IB Fallopian Tube Cancer Stage IB Ovarian Cancer Stage IB Ovarian Germ Cell Tumor Stage IC Fallopian Tube Cancer Stage IC Ovarian Cancer Stage IC Ovarian Germ Cell Tumor Stage II Ovarian Cancer Stage II Uterine Corpus Cancer Stage II Vaginal Cancer Stage II Vulvar Cancer Stage IIA Cervical Cancer Stage IIA Fallopian Tube Cancer Stage IIA Ovarian Cancer Stage IIA Ovarian Germ Cell Tumor Stage IIB Cervical Cancer Stage IIB Fallopian Tube Cancer Stage IIB Ovarian Cancer Stage IIB Ovarian Germ Cell Tumor Stage IIC Fallopian Tube Cancer Stage IIC Ovarian Cancer Stage IIC Ovarian Germ Cell Tumor Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor Stage III Cervical Cancer Stage III Uterine Corpus Cancer Stage III Vaginal Cancer Stage III Vulvar Cancer Stage IIIA Fallopian Tube Cancer Stage IIIA Ovarian Cancer Stage IIIA Ovarian Germ Cell Tumor Stage IIIA Primary Peritoneal Cancer Stage IIIB Fallopian Tube Cancer Stage IIIB Ovarian Cancer Stage IIIB Ovarian Germ Cell Tumor Stage IIIB Primary Peritoneal Cancer Stage IIIC Fallopian Tube Cancer Stage IIIC Ovarian Cancer Stage IIIC Ovarian Germ Cell Tumor Stage IIIC Primary Peritoneal Cancer Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor Stage IV Fallopian Tube Cancer Stage IV Ovarian Cancer Stage IV Primary Peritoneal Cancer Stage IV Uterine Corpus Cancer Stage IVA Cervical Cancer Stage IVA Vaginal Cancer Stage IVB Cervical Cancer Stage IVB Vaginal Cancer Stage IVB Vulvar Cancer Uterine Corpus Cancer Uterine Corpus Leiomyosarcoma Vulvar Squamous Cell Carcinoma

Interventions Laboratory Biomarker Analysis

Updated 12 times since 2017 Last updated: Oct 26, 2016 Started: Jun 30, 1992 Primary completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Borderline Ovarian Clear Cell Tumor and Borderline Ovarian Serous Tumor, this trial is completed. The trial is conducted by Gynecologic Oncology Group and has accumulated 12 data snapshots since 1992. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Feb 2021 — Dec 2021 [monthly]

Completed

▶ Show 7 earlier versions

Jan 2021 — Feb 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed
Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jun 1992

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Akron, United States , Albuquerque, United States , Allentown, United States , Amarillo, United States , Ann Arbor, United States , Ashland, United States , Atlanta, United States , Auburn, United States , Augusta, United States and 117 more locations